Drug Shortage Report for LENVIMA

Last updated on 2019-03-01 History
Report ID 76473
Drug Identification Number 02468220
Brand name LENVIMA
Common or Proper name Lenvatinib
Company Name EISAI LIMITED
Market Status MARKETED
Active Ingredient(s) LENVATINIB
Strength(s) 8MG
Dosage form(s) CAPSULE
Route of administration ORAL
Packaging size 8mg daily-dose carton containing 6 blister cards (each 5-day blister card contains ten 4mg capsules)
ATC code L01XE
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug.
Anticipated start date
Actual start date 2019-02-19
Estimated end date
Actual end date 2019-02-28
Shortage status Resolved
Updated date 2019-03-01
Company comments Supply of 4mg capsules available through other daily-dose configurations. Contact for more information.
Health Canada comments
Tier 3 Status No
Contact Address 6925 CENTURY AVE, SUITE 701
MISSISSAUGA, ONTARIO
CANADA L5N 7K2
Company contact information Tammy Mitchell-Moore - Director, Regulatory Affairs 905-814-2312 / tammy_mitchellmoore@eisai.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v11 2019-03-01 French Compare
v10 2019-03-01 English Compare
v9 2019-03-01 English Compare
v8 2019-03-01 English Compare
v7 2019-03-01 French Compare
v6 2019-03-01 English Compare
v5 2019-03-01 English Compare
v4 2019-03-01 English Compare
v3 2019-02-21 French Compare
v2 2019-02-21 English Compare
v1 2019-02-21 English Compare

Showing 1 to 11 of 11